SCHEMBL4491900

SCHEMBL4491900

CC(=O)N(CCN(C)C)c1ccc(N/C(=C2\C(=O)Nc3cc(F)ccc32)c2ccc(N3CCOC3=O)cc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELOVL6 Q9H5J4 1/20 0.36
KDM1A O60341 4/20 0.35
MAOA P21397 4/20 0.35
MAOB P27338 4/20 0.35
RCOR1 Q9UKL0 4/20 0.35
BACE1 P56817 1/20 0.33
KDM1B Q8NB78 2/20 0.31
NAMPT P43490 2/20 0.30
TGM2 P21980 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
ALOX15 P16050 1/20 0.30
ALOX12 P18054 1/20 0.30
MAPK1 P28482 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
PDGFRB P09619 1/20 0.30
RAF1 P04049 1/20 0.30
HTR1F P30939 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491904 1.00 ELOVL6 (0.36) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4498478 0.96 ELOVL6 (0.35) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4498482 0.96 ELOVL6 (0.35) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4498816 0.91 KDM1A (0.35) KDM1AMAOAMAOBRCOR1KDM1B
SCHEMBL4498819 0.91 KDM1A (0.35) KDM1AMAOAMAOBRCOR1KDM1B
SCHEMBL4504837 0.88 ELOVL6 (0.35) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4504828 0.88 ELOVL6 (0.35) ELOVL6KDM1AMAOAMAOBRCOR1
SCHEMBL4503967 0.87 KDM1A (0.34) KDM1AMAOAMAOBRCOR1KDM1B
SCHEMBL4503962 0.87 KDM1A (0.34) KDM1AMAOAMAOBRCOR1KDM1B
SCHEMBL4492562 0.87 ELOVL6 (0.37) ELOVL6KDM1AMAOAMAOBRCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR ELOVL6 2925/4885KDM1A 1808/4885MAOA 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.